Assesment and Comparison of Osteoporosis Risk Factors After Stroke

Comparison of Osteoporosis Risk in the Subacute and Chronic Periods Following Stroke and Evaluation of Factors Increasing Osteoporosis

The aim of this study is to evaluate the effect of these factors and stroke itself on osteoporosis developing after stroke. Thus, the expected benefit of the study is to contribute to the identification and determination of the need for treatment in high-risk patients through further studies. There are no expected risks from the study.

Study Overview

• Status: Recruiting
• Conditions: Stroke Osteoporosis
• Intervention / Treatment: Diagnostic test: Bone Mineral Density

• Study Type: Observational
• Enrollment (Estimated): 84

Contacts and Locations

• Study Contact: Name: Ayse Naz Kalem Ozgen, Specialist; Phone Number: +90 0312 797 00 00; Email: kalemnaz@gmail.com

Study Locations

• Turkey (Türkiye)
  • Yenimahalle
    • Ankara, Yenimahalle, Turkey (Türkiye), 06010
      • Recruiting
      • Ankara Etlik City Hospital
      • Contact: Ayse Naz Kalem Ozgen, Specialist; Phone Number: +90 0312 797 00 00; Email: kalemnaz@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Fifty-six stroke patients receiving inpatient treatment will be evaluated. In addition, patients who have visited the outpatient clinic and have already undergone BMD scanning for osteoporosis screening, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be randomly included in the study.

Description

Inclusion Criteria:

1. Followed by ischemic or hemorrhagic stroke
2. Between 1 week and 6 months or >1 year has passed since the date of the event
3. Being between 55 and 85 years of age

Exclusion Criteria:

1. The patient has additional neurological conditions besides stroke
2. The patient has a psychiatric condition
3. History of recurrent stroke
4. BMD scan performed within the last year for stroke patients
5. Having received osteoporosis treatment before or after the stroke
6. The patient having a fragility fracture before the stroke
7. The patient having a hip fracture or hip prosthesis
8. The patient having an additional condition that affects physical function before the stroke (amputation, severe fracture)
9. The patient has an additional disease or medication use that could cause secondary osteoporosis
10. The patient's stroke did not cause physical function loss

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy Volunteer	Diagnostic test: Bone Mineral Density; Patients who have had a stroke and are at risk of fracture, and for whom routine assessment requires Bone Mineral Density (BMD) testing, will be included in the study. In addition, patients who have already undergone BMD testing for osteoporosis screening and who present to the outpatient clinic, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be included in the study.
Subacute Stroke	Diagnostic test: Bone Mineral Density; Patients who have had a stroke and are at risk of fracture, and for whom routine assessment requires Bone Mineral Density (BMD) testing, will be included in the study. In addition, patients who have already undergone BMD testing for osteoporosis screening and who present to the outpatient clinic, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be included in the study.
Chronic Stroke	Diagnostic test: Bone Mineral Density; Patients who have had a stroke and are at risk of fracture, and for whom routine assessment requires Bone Mineral Density (BMD) testing, will be included in the study. In addition, patients who have already undergone BMD testing for osteoporosis screening and who present to the outpatient clinic, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be included in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Bone Mineral Density	First day of hospitalization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brunnstrom		First day of hospitalization
Modified Barthel Index		First day of hospitalization
Modified Ashworth Scale		First day of hospitalization
Modified Fall Impact Scale		First day of hospitalization
Vitamin D, prealbumin, and albumin		First day of hospitalization
Baseline Digital Hand Dynamometer 198 LB/90 kg	Patients' muscle strength will be measured using a Baseline Digital Hand Dynamometer at 198 LB/90 kg for both the dominant and non-dominant extremities.	First day of hospitalization
Measurements of quadriceps muscle thickness and biceps muscle thickness	Regional sarcopenia of the plegic and non-plegic extremities will also be assessed using the STAR formula with measurements of anterior thigh muscle thickness and anterior arm muscle thickness by ultrasound.	First day of hospitalization

Collaborators and Investigators

• Sponsor: Ankara Etlik City Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 5, 2025
• Primary Completion (Estimated): May 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: November 13, 2025
• First Submitted That Met QC Criteria: November 13, 2025
• First Posted (Actual): November 14, 2025

Study Record Updates

• Last Update Posted (Actual): February 24, 2026
• Last Update Submitted That Met QC Criteria: February 22, 2026
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Bone Density
• Other Study ID Numbers: AEŞH-BADEK-2025-478

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No